✨ Free AI Report
Aktis Oncology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aktis Oncology, Inc.
Company Research

Aktis Oncology, Inc.: Business Overview, Financials & Competitive Analysis

Aktis Oncology, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Well-capitalized clinical-stage radiopharmaceutical company with proprietary platform, multiple Phase 1b trials underway, and runway to 2029 with demonstrated pharma validation. Cash position of $517.3 million as of June 30, 2026, reflecting net proceeds from the Company's IPO in January 2026, with sufficient runway expected to fund operations into 2029.

What is Aktis Oncology, Inc.'s industry? Aktis Oncology, Inc. (aktisoncology.com) operates in Pharmaceuticals. AskCyborg classifies Aktis Oncology, Inc. under Pharmaceuticals in its company registry.

Aktis Oncology (NASDAQ:AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platfo...

7/ 10Strong

Cyborg Score thesis

Well-capitalized clinical-stage radiopharmaceutical company with proprietary platform, multiple Phase 1b trials underway, and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aktis Oncology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Aktis Oncology, Inc.

AskCyborg analysts argue the bull and bear cases for Aktis Oncology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aktis Oncology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Aktis Oncology, Inc. Overview

Pro stress-test →

Aktis Oncology (NASDAQ:AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies. Prior to its IPO, Aktis banked $346 million in private funding to advance its pipeline of radiopharmaceuticals, including investments from MPM BioImpact, Vida Ventures and RA Capital.

Strategic Profile

Pro stress-test →

The Company has built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy to a broader range of patient populations. Aktis' most advanced clinical-stage pipeline program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer.

Competitive Landscape

Pro stress-test →

Aktis targets well-established tumor antigens; AKY-1189 targets Nectin-4, the same protein targeted by Pfizer's Padcev in bladder cancer. Key competitors in radiopharmaceutical oncology include established radioligand therapy developers and emerging miniprotein-based platforms.

Industry Context

Aktis Oncology, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2020 · Headquarters: Boston, Massachusetts · Employees: 76 full-time employees as of September 2025 · Revenue: $8.28M (trailing 12 months as of March 31, 2026); estimated $0 commercial revenue (clinical-stage company) · Market cap: $1.3B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aktis Oncology, Inc..

  • (January 2026) Aktis raises $318M in 2026’s first biotech IPO | BioPharma Dive — Aktis raises $318M in 2026’s first biotech IPO.
  • AKY-2519 clinical imaging and dosimetry data presented at ASCO (June 2026) generated enthusiasm; two-trial strategy initiated with Phase 1b in PLUVICTO-naive/experienced mCRPC patients to enable broad indication evaluation
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Aktis raises $318M in 2026’s first biotech IPO | BioPharma Dive — Aktis raises $318M in 2026’s first biotech IPO.
  • March 2026FDA cleared IND application for AKY-2519; Phase 1b trial initiated in metastatic castration-resistant prostate cancer (mCRPC) patients
  • +1 moreTrack every material event for Aktis Oncology, Inc. as it happens. Explore monitoring →
Get alerted when Aktis Oncology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

NovartisRadiopharmaceutical for neuroendocrine tumors→Advanced Accelerator ApplicationsRadiopharmaceutical developer for neuroendocrine and oncology applications→Lantheus HoldingsMedical imaging and radiopharmaceutical company→TeranosticsRadiopharmaceutical company developing targeted cancer treatments→Ayala PharmaceuticalsOncology-focused biopharmaceutical company with radiopharmaceutical programs→

Compare Aktis Oncology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aktis Oncology, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Aktis Oncology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aktis Oncology, Inc. and its top competitor on Cyborg Score”
“What did Aktis Oncology, Inc. do this quarter?”
“Is Aktis Oncology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aktis Oncology, Inc. do?+
Aktis Oncology (NASDAQ:AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platfo...
What is Aktis Oncology, Inc.'s Cyborg Score?+
Aktis Oncology, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aktis Oncology, Inc.'s main competitors?+
Named competitors include Novartis, Advanced Accelerator Applications, Lantheus Holdings, Teranostics. The full competitive landscape is in the AskCyborg report.
How can I get the full Aktis Oncology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aktis Oncology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aktis Oncology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.